Practice guidelines are not intended as absolute requirements. The use of these practice guidelines does not in any way project or guarantee any specific benefit in outcome or survival.
The judgment of the healthcare professional based on individual circumstances of the patient must always take precedence over the recommendations in these guidelines.
The guidelines offer basic recommendations that are supported by review and analysis of the pertinent available current literature, other national and international guidelines, and by the blend of expert opinion and clinical practicality. The "intensive care unit" (ICU) or "critically ill" patient is not a homogeneous population. Many of the studies on which the guidelines are based are limited by sample size, patient heterogeneity, variability in definition of disease state and severity of illness, lack of baseline nutritional status, and lack of statistical power for analysis. Whenever possible, these factors are taken into account and the grade of statement will reflect the power of the data. One of the major methodologic problems with any guideline is defining the exact population to be included.
Periodic Guideline Review and Update
These guidelines may be subject to periodic review and revision based on new peer-reviewed critical care nutrition literature and practice.
Target Patient Population for Guidelines
These guidelines are intended for the adult medical and surgical critically ill patient populations expected to require an ICU stay of greater than 2 or 3 days and are not intended for those patients in the ICU for temporary monitoring or those who have minimal metabolic or traumatic stress. These guidelines are based on populations, but like any other therapeutic treatment in an ICU patient, nutrition requirements and techniques of access should be tailored to the individual patient.
Target Audience
The intended use of these guidelines is for all individuals involved in the nutrition therapy of the critically ill, primarily physicians, nurses, dietitians, pharmacists, and respiratory and physical therapists where indicated.
Methodology
A list of guideline recommendations was compiled by experts on the Guidelines Committee for the two societies, each of which represented clinically applicable definitive statements of care or specific action statements. Prospective randomized controlled trials were used as the primary source to support guideline statements, with each study being evaluated and given a level of evidence. The overall grade for the recommendation was based on the number and level of The American College of Critical Care Medicine (ACCM), which honors individuals for their achievements and contributions to multidisciplinary critical care medicine, is the consultative body of the Society of Critical Care Medicine (SCCM) that possesses recognized expertise in the practice of critical care. The College has developed administrative guidelines and clinical practice parameters for the critical care practitioner. New guidelines and practice parameters are continually developed, and currents ones are systematically reviewed and revised.
From the Department of Surgery (RGM, GC), Medical College of Georgia, Augusta, GA; Division of Gastroenterology/Hepatology (SAM), University of Louisville School of Medicine, Louisville, KY; Saint Elizabeth Hospital (VWV), Youngstown, OH; Nursing Researchinvestigative studies referable to that guideline. Large studies warranting level I evidence were defined as those with Ն100 patients or those which fulfilled end point criteria predetermined by power analysis. The level of evidence for uncontrolled studies was determined by whether they included contemporaneous controls (level III), historical controls (level IV), or no controls (level V, equal to expert opinion) ( Table 1) (1). Review articles and consensus statements were considered expert opinion, and were designated the appropriate level of evidence. Meta-analyses were used to organize the information and to draw conclusions about an overall treatment effect from multiple studies on a particular subject. The grade of recommendation, however, was based on the level of evidence of the individual studies. An A or B grade recommendation required at least one or two large positive randomized trials supporting the claim, whereas a C grade recommendation required only one small supportive randomized investigation. The rationale for each guideline statement was used to clarify certain points from the studies, to identify controversies, and to provide clarity in the derivation of the final recommendation. Significant controversies in interpretation of the literature were resolved by consensus of opinion of the committee members, which in some cases led to a downgrade of the recommendation. Following an extensive review process by external reviewers, the final guideline manuscript was reviewed and approved by the Boards for both the American Society for Parenteral and En-
INTRODUCTION
The significance of nutrition in the hospital setting cannot be overstated. This significance is particularly noted in the ICU. Critical illness is typically associated with a catabolic stress state in which patients commonly demonstrate a systemic inflammatory response. This response is coupled with complications of increased infectious morbidity, multiorgan dysfunction, prolonged hospitalization, and disproportionate mortality. During the past three decades, the understanding of the molecular and biological effects of nutrients in maintaining homeostasis in the critically ill population has made exponential advances. Traditionally, nutrition support in the critically ill population was regarded as adjunctive care designed to provide exogenous fuels to support the patient during the stress response. This support had three main objectives: to preserve lean body mass, maintain immune function, and avert metabolic complications. Recently, these goals have become more focused on nutrition therapy, specifically attempting to attenuate the metabolic response to stress, prevent oxidative cellular injury, and favorably modulate the immune response. Nutritional modulation of the stress response to critical illness includes early enteral nutrition (EN), appropriate macronutrient and micronutrient delivery, and meticulous glycemic control. Delivering early nutrition support therapy, primarily using the enteral route, is seen as a proactive therapeutic strategy that may reduce disease severity, diminish complications, decrease length of stay (LOS) in the ICU, and favorably impact patient outcome.
A. Initiate Enteral Feeding
A1. Traditional nutrition assessment tools (albumin, prealbumin, and anthropometry) are not validated in critical care. Before initiation of feedings, assessment should include evaluation of weight loss and previous nutrient intake before admission, level of disease severity, comorbid conditions, and function of the gastrointestinal (GI) tract (grade E).
Rationale. In the critical care setting, the traditional protein markers (albumin, prealbumin, transferrin, retinol binding protein) are a reflection of the acute phase response (increases in vascular permeability and reprioritization of hepatic protein synthesis) and do not accurately represent nutrition status in the ICU setting. Anthropometrics are not reliable in assessment of nutrition status or adequacy of nutrition therapy (2, 3) .
A2. Nutrition support therapy in the form of EN should be initiated in the critically ill patient who is unable to maintain volitional intake (grade C).
Rationale. EN supports the functional integrity of the gut by maintaining tight junctions between the intraepithelial cells, stimulating blood flow, and inducing the release of trophic endogenous agents (such as cholecystokinin, gastrin, bombesin, and bile salts). EN maintains structural integrity by maintaining villous height and supporting the mass of secretory IgA-producing immunocytes, which comprise the gutassociated lymphoid tissue, and in turn contribute to mucosal-associated lymphoid tissue at distant sites such as the lungs, liver, and kidneys (4 -6).
Adverse changes in gut permeability from loss of functional integrity is a dynamic phenomenon that is time dependent (channels opening within hours of the major insult or injury). The consequences of the permeability changes include increased bacterial challenge (engagement of gut-associated lymphoid tissue with enteric organisms), risk for systemic infection, and greater likelihood of multiorgan dysfunction syndrome (4, 5, 7). As disease severity worsens, increases in gut permeability are amplified and the enteral route of feeding is more likely to favorably impact outcome pa- Table 1 . Grading system used for these guidelines Grade of recommendation A-Supported by at least two level I investigations B-Supported by one level I investigation C-Supported by level II investigations only D-Supported by at least two level III investigations E-Supported by level IV or level V evidence Level of evidence I-Large, randomized trials with clear-cut results; low risk of false-positive (alpha) error or false-negative (beta) error II-Small, randomized trials with uncertain results; moderate to high risk of false-positive (alpha) and/or false-negative (beta) error III-Nonrandomized, contemporaneous controls IV-Nonrandomized, historical controls V-Case series, uncontrolled studies, and expert opinion Note: Large studies warranting level I evidence were defined as those with Ն100 patients or those which fulfilled endpoint criteria predetermined by power analysis. Meta-analyses were used to organize information and to draw conclusions about overall treatment effect from multiple studies on a particular subject. The grade of recommendation, however, was based on the level of evidence of the individual studies.
Adapted and printed with permission from Dellinger et al (1) .
rameters of infection, organ failure, and hospital LOS (compared with the parenteral route) (8).
The specific reasons for providing early EN are to maintain gut integrity, modulate stress and the systemic immune response, and attenuate disease severity (6, 8, 9). Additional end points of EN therapy include use of the gut as a conduit for the delivery of immunemodulating agents and use of enteral formulations as an effective means for stress ulcer prophylaxis.
Nutrition support therapy (also called "specialized" or "artificial" nutrition therapy) refers to the provision of enteral tube feeding or parenteral nutrition (PN). "Standard therapy" (STD) refers to a patient's own volitional intake without provision of specialized nutrition support therapy. The importance of promoting gut integrity with regard to patient outcome is being strengthened by clinical trials comparing critically ill patients fed by EN to those receiving STD. In a recent meta-analysis (10) in elective GI surgery and surgical critical care, patients undergoing a major operation who were given early postoperative EN experienced significant reductions in infection (relative risk [RR] ϭ 0.72; 95% confidence interval [CI] 0.54 -0.98; p ϭ 0.03), hospital LOS (mean 0.84 days; range 0.36 -1.33 days; p ϭ 0.001), and a trend toward reduced anastomotic dehiscence (RR ϭ 0.53; 95% CI 0.26 -1.08; p ϭ 0.08), when compared with similar patients receiving no nutrition support therapy (10 -16). In a metaanalysis (17) of patients undergoing surgery for complications of severe acute pancreatitis, those placed on EN 1 day after surgery showed a trend toward reduced mortality compared with controls randomized to STD (RR ϭ 0.26; 95% CI 0.06 -1.09; p ϭ 0.06) (17-19) ( Table 2) (11-16, 18, 19).
A3. EN is the preferred route of feeding over PN for the critically ill patient who requires nutrition support therapy (grade B).
Rationale. In the majority of critically ill patients, it is practical and safe to use EN instead of PN. The beneficial effects of EN when compared with PN are well documented in numerous prospective randomized controlled trials involving a variety of patient populations in critical illness, including trauma, burns, head injury, major surgery, and acute pancreatitis (8, 20 -22). Although few studies have shown a differential effect on mortality, the most consistent outcome effect from EN is a reduction in infectious morbidity (generally pneumonia and central line infections in most patient populations, and specifically abdominal abscess in trauma patients) (20). In many studies, further benefits are seen from significant reductions in hospital LOS (21), cost of nutrition therapy (21), and even return of cognitive function (in patients with head injuries) (23). All six meta-analyses that compared EN vs. PN showed significant reductions in infectious morbidity with use of EN (21, 24 -28). Noninfective complications (RR ϭ 4.9; 95% CI 0.3-9.5; p ϭ 0.04) and reduced hospital LOS (weighted mean difference [WMD] ϭ 1.20 days; 95% CI 0.38 -2.03; p ϭ 0.004) were seen with use of EN compared with PN in one meta-analysis by Peter et al (28). Five of the meta-analyses showed no difference in mortality between the two routes of nutrition support therapy (21, 24, 26 -28). One meta-analysis by Simpson and Doig (25) showed a significantly lower mortality (RR ϭ 0.51; 95% CI 0.27-0.97; p ϭ 0.04) despite a significantly higher incidence of infectious complications (RR ϭ 1.66; 95% CI 1.09 -2.51; p ϭ 0.02) with use of PN compared with EN (Table  3) Rationale. Attaining access and initiating EN should be considered as soon as fluid resuscitation is completed and the patient is hemodynamically stable. A "window of opportunity" exists in the first 24 -72 hours following admission or the onset of a hypermetabolic insult. Feedings started within this time frame, compared with feedings started later (after 72 hours), are associated with less gut permeability, diminished activation and release of inflammatory cytokines, i.e., tumor necrosis factor and reduced systemic endotoxemia (21). One meta-analysis by Heyland et al (21) showed a trend toward reduced infectious morbidity (RR ϭ 0.66; 95% CI 0.36 -1.22; p ϭ 0.08) and mortality (RR ϭ 0.52; 95% CI 0.25-1.08; p ϭ 0.08), whereas a second by Marik and Zaloga (62) showed significant reductions in infectious morbidity (RR ϭ 0.45; 95% CI 0.30 -0.66; p ϭ 0.00006) and hospital LOS (mean 2.2 days, 95% CI 0.81-3.63 days; p ϭ 0.001) with early EN compared with delayed feedings (Table 4) (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) . A5. In the setting of hemodynamic compromise (patients requiring significant hemodynamic support including high dose catecholamine agents, alone or in combination with large volume fluid or blood product resuscitation to maintain cellular perfusion), EN should be withheld until the patient is fully resuscitated and/or stable (grade E).
Rationale. At the height of critical illness, EN is being provided to patients who are prone to GI dysmotility, sepsis, and hypotension, and thus are at increased risk for subclinical ischemia/ reperfusion injury involving the intestinal microcirculation. Ischemic bowel is a rare complication of EN, occurring in less than 1% of cases (73, 74) . EN-related ischemic bowel has been reported most often in the past with use of surgical jejunostomy tubes. However, more recently, this complication has been described with use of nasojejunal tubes (75) . EN intended to be infused into the small bowel should be withheld in patients who are hypotensive (mean arterial blood pressure Ͻ60 mm Hg), particularly if clinicians are initiating use of catecholamine agents (e.g., norepinephrine, phenylephrine, epinephrine, dopamine) or escalating the dose of such agents to maintain hemodynamic stability. EN may be provided with caution to patients either into the stomach or small bowel on stable low doses of pressor agents (76) , but any signs of intolerance (abdominal distention, increasing nasogastric tube output or gastric residual volumes, decreased passage of stool and flatus, hypoactive bowel sounds, increasing metabolic acidosis, and/or base deficit) should be closely scrutinized as possible early signs of gut ischemia. A6. In the ICU patient population, neither the presence nor absence of bowel sounds nor evidence of passage of flatus and stool is required for the initiation of enteral feeding (grade B).
Rationale. The literature supports the concept that bowel sounds and evidence of bowel function, i.e., passing flatus or stool, are not required for initiation of enteral feeding. GI dysfunction in the ICU setting occurs in 30% to 70% of patients, depending on the diagnosis, premorbid condition, ventilation mode, medications, and metabolic state (77) .
Proposed mechanisms of ICU and postoperative GI dysfunction can be separated into three general categories: mucosal barrier disruption, altered motility and atrophy of the mucosa, and reduced mass of gut-associated lymphoid tissue.
Bowel sounds are only indicative of contractility and do not necessarily relate to mucosal integrity, barrier function, or absorptive capacity. Success at attaining nutrition goals within the first 72 hours ranges from 30% to 85%. When ICU enteral feeding protocols are followed, rates of GI tolerance in the range of 70% to 85% can be achieved (76) . Ten randomized clinical trials (63) (64) (65) (66) (67) (68) (69) (70) (71) (72) , the majority in surgical critically ill, have reported feasibility and safety of enteral feeding within the initial 36 -48 hours of admission to the ICU. The grade of this recommendation is based on the strength of the literature supporting A3, where patients in the experimental arm of the abovementioned studies were successfully started on EN within the first 36 hours of admission (regardless of clinical signs of stooling, flatus, or borborygmi) ( Rationale. Multiple studies have evaluated gastric vs. jejunal feeding in various medical and surgical ICU settings. One level II study comparing gastric vs. jejunal feeding showed significantly less gastroesophageal reflux with small bowel feeding (78) . In a nonrandomized prospective study using a radioisotope in an enteral formulation, esophageal reflux was reduced significantly with a trend toward reduced aspiration as the level of infusion was moved from the stomach down through the third por- tion of the duodenum (79) . Three metaanalyses have been published comparing gastric with postpyloric feeding in the ICU setting (80 -82) . Only one of these meta-analyses showed a significant reduction in ventilator-associated pneumonia with postpyloric feeding (RR ϭ 0.76; 95% CI 0.59 -0.99, p ϭ 0.04) (82) , an effect heavily influenced by one study by Taylor et al (23). With removal of this study from the metaanalysis, the difference was no longer significant. The two other meta-analyses (which did not include the Taylor study) showed no difference in pneumonia between gastric and postpyloric feeding (80, 81) . Although one showed no difference in ICU LOS (80) , all three meta-analyses showed no significant difference in mortality between gastric and postpyloric feeding (80 -82) (Table  5) 
to the ICU, no nutrition support therapy (ie, STD) should be provided (grade C). In the patient who was previously healthy before critical illness with no evidence of protein-calorie malnutrition, use of PN should be reserved and initiated only after the first 7 days of hospitalization (when EN is not available) (grade E).
Rationale. These two recommendations are the most controversial in the guidelines, are influenced primarily by two meta-analyses, and should be interpreted very carefully in application to patient care (24, 92). Both meta-analyses compared use of PN with STD (where no nutrition support therapy was provided). In critically ill patients in the absence of preexisting malnutrition (when EN is not available), Braunschweig et al aggregated seven studies (93) (94) (95) (96) (97) (98) (99) and showed that use of STD was associated with significantly reduced infectious morbidity (RR ϭ 0.77; 95% CI 0.65-0.91; p Ͻ 0.05) and a trend toward reduced overall complications (RR ϭ 0.87; 95% CI 0.74 -1.03; p not provided) compared with use of PN (24). In the same circumstances (critically ill, no EN available, and no evidence of malnutrition), Heyland et al aggregated four studies (96, 97, 100, 101) and showed a significant increase in mortality with use of PN (RR ϭ 0.1.78; 95% CI 1.11-2.85; p Ͻ 0.05) and a trend toward greater rate of complications (RR ϭ 2.40; 95% CI 0.88 -6.58; p not provided), when compared with STD (92) ( Table 6 ) .
With increased duration of severe illness, priorities between STD and PN become reversed. Sandstrom et al first showed that after the first 14 days of hospitalization had elapsed, continuing to provide no nutrition therapy was associated with significantly greater mortality (21% vs. 2%, p Ͻ 0.05) and longer hospital LOS (36.3 days vs. 23.4 days, p Ͻ 0.05), when compared respectively with use of PN (96) . The authors of both metaanalyses speculated as to the appropriate length of time before initiating PN in a patient on STD who has not begun to eat spontaneously (Braunschweig et al recommending 7-10 days, Heyland et al recommending 14 days) (24, 92). Conflicting data were reported in a Chinese study of patients with severe acute pancreatitis. In this study, a significant step-wise improvement was seen in each clinical outcome parameter (hospital LOS, pancreatic infection, overall complications, and mortality) when comparing patients randomized to STD vs. PN vs. PN with parenteral glutamine, respectively (121) . Because of the discrepancy, we attempted to contact the authors of this latter study to get validation of results, but were unsuccessful. The final recommendation was based on the overall negative treatment effect of PN over the first week of hospitalization seen in the two metaanalyses (24, 92). Although the literature cited recommends withholding PN for 10-14 days, the Guidelines Committee expressed concern that continuing to provide STD (no nutrition support therapy) beyond 7 days would lead to deterioration of nutritional status and an adverse effect on clinical outcome.
B2. If there is evidence of protein-calorie malnutrition on admission and EN is not feasible, it is appropriate to initiate PN as soon as possible following admission and adequate resuscitation (grade C).
Rationale. In the situation where EN is not available and evidence of proteincalorie malnutrition is present (usually defined by recent weight loss of Ͼ10% to 15% or actual body weight less than 90% of ideal body weight), initial priorities are reversed and use of PN has a more favorable outcome than STD (Table 6 ) .
In the meta-analysis by Heyland et al, use of PN in malnourished ICU patients was associated with significantly fewer overall complications (RR ϭ 0.52; 95% CI 0.30 -0.91; p Ͻ 0.05) than STD (92) . In the meta-analysis by Braunschweig et al, STD in malnourished ICU patients was associated with significantly higher risk for mortality (RR ϭ 3.0; 95% CI 1.09 -8.56; p Ͻ 0.05) and a trend toward higher rate of infection (RR ϭ 1.17; 95% CI 0.88 -1.56; p not provided) compared with use of PN (24). For these patients, when EN is not available, there should be little delay in initiating PN after admission to the ICU.
B3. If a patient is expected to undergo major upper GI surgery and EN is not feasible, PN should be provided under very specific conditions:
• If the patient is malnourished, PN should be initiated 5 to 7 days preoperatively and continued into the postoperative period (grade B).
• PN should not be initiated in the immediate postoperative period, but should be delayed for 5-7 days (should EN continue not to be feasible) (grade B).
• PN therapy provided for a duration of less than 5-7 days would be expected to have no outcome effect and may result in increased risk to the patient. Thus, PN should be initiated only if the duration of therapy is anticipated to be Ն7 days (grade B).
Rationale. One population of patients who has shown more consistent benefit of PN over STD involves those patients undergoing major upper GI surgery (esophagectomy, gastrectomy, pancreatectomy, or other major reoperative abdominal procedures), especially if there is evidence of preexisting protein-calorie malnutrition and the PN is provided under specific conditions (24, 92). Whereas critically ill patients in the Heyland meta-analysis experienced increased mortality with use of PN compared with STD (see rationale for B1 earlier), surgical patients saw no treatment effect with PN regarding mortality (RR ϭ 0.91; 95% CI 0.68 -1.21; p ϭ not significant) (92) . Critically ill patients experienced a trend toward increased complications, whereas surgical patients saw significant reductions in complications with use of PN regarding mortality (RR ϭ 2.40; 95% CI 0.88 -6.58; p Ͻ 0.05) (92) .
These benefits were noted when PN was provided preoperatively for a minimum of 7-10 days and then continued through the perioperative period. In an earlier metaanalysis by Detsky et al (130) (130) . As a result, only one study showed a treatment effect (95) and the overall meta-analysis showed no statistically significant benefit from PN (130) . In contrast, a later meta-analysis by Klein et al (131) aggregated the data from 13 studies (95, 98, 103, 105, 111, (113) (114) (115) (116) (117) (118) (119) (120) , all of which provided PN for Ն7 days (131) . Six of the studies showed significant beneficial treatment effects from use of PN (95, 103, 105, 111, 115, 120) , with the pooled data from the overall meta-analysis showing a significant 10% decrease in infectious morbidity compared with STD (131) ( Table 6 ) .
It is imperative to be aware that the beneficial effect of PN is lost if given only postoperatively. Aggregation of data from nine studies that evaluated routine postoperative PN (93, 94, 96, 99 -101, 104, 109, 122) showed a significant 10% increase in complications compared with STD (131) . Because of the adverse outcome effect from PN initiated in the immediate postoperative period, Klein et al recommended delaying PN for 5-10 days following surgery if EN continues not to be feasible (131) . Calories provided via infusion of propofol should be considered when calculating the nutrition regimen. Although it is often difficult to provide 100% of goal calories by the enteral route, studies in which a protocol was used to increase delivery of EN have shown that delivering a volume of EN where the level of calories and protein provided is closer to goal improves outcome (133, 134) . This recommendation is supported by two level II studies in which those patients who by protocol randomization received a greater volume of EN experienced significantly fewer complications and less infectious morbidity (23), as well as shorter hospital lengths of stay, and a trend toward lower mortality (135) than those patients receiving lower volume.
C. Dosing of Enteral Feeding

C1. The target goal of EN (defined by energy requirements) should be deter-mined and clearly identified at the time of initiation of nutrition support therapy (grade C). Energy requirements may be
C2. Efforts to provide Ͼ50% to 65% of goal calories should be made to achieve the clinical benefit of EN over the first week of hospitalization (grade C).
Rationale. The impact of early EN on patient outcome appears to be a dosedependent effect. "Trickle" or trophic feeds (usually defined as 10 -30 mL/hr) may be sufficient to prevent mucosal atrophy, but may be insufficient to achieve the usual end points desired of EN therapy. Studies suggest that Ͼ50% to 65% of goal calories may be required to prevent increases in intestinal permeability in burn and bone-marrow transplant patients, to promote faster return of cognitive function in head injury patients, and to improve outcome from immunemodulating enteral formulations in critically ill patients (5, 23, 133, 136) . This recommendation is supported by one level II (23) and one level III study (136) where increases in the percent goal calories infused from a range of 37% to 40% up to 59% to 64% improved clinical outcome.
C3. If unable to meet energy requirements (100% of target goal calories) after 7-10 days by the enteral route alone, consider initiating supplemental PN (grade E). Initiating supplemental PN before this 7-10 day period in the patient already on EN does not improve outcome and may be detrimental to the patient (grade C).
Rationale. Early on, EN is directed toward maintaining gut integrity, reducing oxidative stress, and modulating systemic immunity. In patients already receiving some volume of EN, use of supplemental PN over the first 7-10 days adds cost (137, 138) and appears to provide no additional benefit (42, [137] [138] [139] [140] . In one small study in burn patients, EN supplemented with PN was associated with a significant increase in mortality (63% vs. 26%, p Ͻ 0.05) when compared, respectively, with hypocaloric EN alone (140) (Table 7 ) (42, 137-140).
As discussed under B1, the optimal time to initiate PN in a patient who is already receiving some volume of enteral feeding is not clear. The reports by Braunschweig and Sandstrom infer that after the first 7-10 days, the need to provide adequate calories and protein is increased to prevent the consequences of deterioration of nutritional status (24, 96 Rationale. In the critical care setting, protein appears to be the most important macronutrient for healing wounds, supporting immune function, and maintaining lean body mass. For most critically ill patients, protein requirements are proportionately higher than energy requirements and, therefore, are not met by provision of routine enteral formulations. The decision to add protein modules should be based on an ongoing assessment of adequacy of protein provision. Unfortunately in the critical care setting, determination of protein requirements is difficult but may be derived with limitations from nitrogen balance, simplistic equations (1.2 to 2.0 g⅐kg Ϫ1 ⅐day Ϫ1 ) or nonprotein calorie:nitrogen ratio (70:1 to 100:1). Serum protein markers (albumin, prealbumin, transferrin, C-reactive protein) are not validated for determining adequacy of protein provision and should not be used in the critical care setting in this manner (141 
g/kg ideal body weight/day for class III (BMI Ն40). Determining energy requirements is discussed elsewhere (grade D).
Rationale. Severe obesity adversely affects patient care in the ICU and increases risk of comorbidities (insulin resistance, sepsis, infections, deep venous thrombosis, organ failure) (142, 143) . Achieving some degree of weight loss may increase insulin sensitivity, improve nursing care, and reduce risk of comorbidities. Providing 60% to 70% of caloric requirements promotes steady weight loss, while infusing protein at a dose of 2.0 -2.5 g/kg ideal body weight/day should approximate protein requirements and neutral nitrogen balance, allowing for adequate wound healing (142) . A retrospective study by Choban and Dickerson (142) indicated that provision of protein at a dose of 2.0 g/kg ideal body weight/day is insufficient for achieving neutral nitrogen balance when the BMI is greater than 40. Use of BMI and ideal body weight is recommended over use of adjusted body weight.
D. Monitoring Tolerance and Adequacy of EN
D1. In the ICU setting, evidence of bowel motility (resolution of clinical ileus) is not required to initiate EN (grade E).
Rationale. Feeding into the GI tract is safe before the emergence of overt evidence of enteric function, such as bowel sounds or the passage of flatus and stool. EN promotes gut motility. As long as the patient remains hemodynamically stable, it is safe and appropriate to feed through mild to moderate ileus (2).
D2. Patients should be monitored for tolerance of EN (determined by patient complaints of pain and/or distention, physical exam, passage of flatus and stool, abdominal radiographs) (grade E). Inappropriate cessation of EN should be avoided (grade E). Holding EN for gastric residual volumes Ͻ500 mL in the absence of other signs of intolerance should be avoided (grade B). Making the patient nil per os (NPO) surrounding the time of diagnostic tests or procedures should be minimized to prevent inadequate delivery of nutrients and prolonged periods of ileus. Ileus may be propagated by NPO status (grade C).
Rationale. A number of factors impede the delivery of EN in the critical care setting (144) . Healthcare providers who prescribe nutrition formulations tend to under-order calories, and thus patients only receive approximately 80% of what is ordered. This combination of underordering and inadequate delivery results in patients receiving only 50% of target goal calories from one day to the next. Cessation of feeding occurs in over 85% of patients for an average of 20% of the infusion time (the reasons for which are avoidable in Ͼ65% of occasions) (144) . Patient intolerance accounts for one third of cessation time, but only half of this represents true intolerance. Other reasons for cessation include remaining NPO after midnight for diagnostic tests and procedures in another third of patients, with the rest being accounted for by elevated gastric residual volumes and tube displacement (144) . In one level II study, patients randomized to continue EN during frequent surgical procedures (burn wound debridement under general anesthesia) had significantly fewer infections than those patients for whom EN was stopped for each procedure (145) .
Gastric residual volumes do not correlate well to incidence of pneumonia (23, 146, 147), measures of gastric emptying (148 -150), or incidence of regurgitation and aspiration (151) . Four level II studies indicate that raising the cutoff value for gastric residual volume (leading to automatic cessation of EN) from a lower number of 50 -150 mL to a higher number of 250 -500 mL does not increase risk for regurgitation, aspiration, or pneumonia (23, 146, 147, 151) . Decreasing the cutoff value for gastric residual volume does not protect the patient from these complications, often leads to inappropriate cessation, and may adversely affect outcome through reduced volume of EN infused (23). Gastric residual volumes in the range of 200 -500 mL should raise concern and lead to the implementation of measures to reduce risk of aspiration, but automatic cessation of feeding should not occur for gastric residual volumes Ͻ500 mL in the absence of other signs of intolerance (152) (Table 8) (23, 146, 147, 151 ).
D3. Use of enteral feeding protocols increases the overall percentage of goal calories provided and should be implemented (grade C).
Rationale. Use of ICU or nurse-driven protocols which define goal infusion rate, 
D4. Patients placed on EN should be assessed for risk of aspiration (grade E). Steps to reduce risk of aspiration should be used (grade E).
The following measures have been shown to reduce risk of aspiration:
• In all intubated ICU patients receiving EN, the head of the bed should be elevated 30°to 45°(grade C).
• For high risk patients or those shown to be intolerant to gastric feeding, delivery of EN should be switched to continuous infusion (grade D).
• Agents to promote motility, such as prokinetic drugs (metoclopramide and erythromycin) or narcotic antagonists (naloxone and alvimopan), should be initiated where clinically feasible (grade C).
• Diverting the level of feeding by postpyloric tube placement should be considered (grade C).
Use of chlorhexidine mouthwash twice a day should be considered to reduce risk of ventilator-associated pneumonia (grade C).
Rationale. Aspiration is one of the most feared complications of EN. Patients at increased risk for aspiration may be identified by a number of factors, including use of a nasoenteric tube, an endotracheal tube and mechanical ventilation, age more than 70 years, reduced level of consciousness, poor nursing care, location in the hospital, patient position, transport out of the ICU, poor oral health, and use of bolus intermittent feedings (152) . Pneumonia and bacterial colonization of the upper respiratory tree are more closely associated with aspiration of contaminated oropharyngeal secretions than regurgitation and aspiration of contaminated gastric contents (155) (156) (157) .
Several methods may be used to reduce the risk of aspiration. As mentioned in recommendation A6, changing the level of infusion of EN from the stomach to the small bowel has been shown to reduce the incidence of regurgitation and aspiration (78, 79) , although the results from three meta-analyses (as discussed under recommendation A6) suggest that any effect in reducing pneumonia is minimal (80 -82) (Table 5) (23, 68, 78, (83) (84) (85) (86) (87) (88) (89) (90) (91) .
Elevating the head of the bed 30°to 45°was shown in one study to reduce the incidence of pneumonia from 23% to 5%, comparing supine with semirecumbent position, respectively (p ϭ 0.018) (158) (Table 9) (158, 159) .
The potential harm from aggressive bolus infusion of EN leading to increased risk of aspiration pneumonia was shown in one study (160) . Level II studies comparing bolus to continuous infusion have shown greater volume with fewer interruptions in delivery of EN with continuous feeding, but no significant difference was seen between techniques with regard to patient outcome (161, 162) (Table 10 ) (161) (162) (163) (164) (165) .
Adding prokinetic agents such as erythromycin or metoclopramide has been shown to improve gastric emptying and tolerance of EN, but has resulted in little change in clinical outcome for ICU patients (166) (Table 11 ) (167) (168) (169) . Use of naloxone infused through the feeding tube (to reverse the effects of opioid narcotics at the level of the gut to improve intestinal motility) was shown in one level II study to significantly increase the volume of EN infused, reduce gastric residual volumes, and decrease the incidence of ventilator-associated pneumonia (compared with placebo) (169) .
Optimizing oral health with chlorhexidine mouthwashes twice daily was shown in two studies to reduce respiratory infection and nosocomial pneumonia in patients undergoing heart surgery (170, 171) . Although studies evaluating use of chlorhexidine in general ICU populations have shown little outcome effect, two studies where chlorhexidine oral care was included in bundled interventions showed significant reductions in nosocomial respiratory infections (172, 173) . Other steps to decrease aspiration risk would include reducing the level of sedation/analgesia when possible, minimizing transport out of the ICU for diagnostic tests and procedures, and moving the patient to a unit with a lower patient/nurse ratio (152, 174) . f %Goal feeding on day 3 (similar to significant differences on day 7).
D5. Blue food coloring and glucose oxidase strips, as surrogate markers for as-
piration, should not be used in the critical care setting (grade E). Rationale. Traditional monitors for aspiration are ineffective. Blue food coloring, an insensitive marker for aspiration, was shown to be associated with mitochondrial toxicity and patient death (175) . The United States Food and Drug Administration through a Health Advisory Bulletin (September 2003) issued a mandate against the use of blue food coloring as a monitor for aspiration in patients on EN (176) . The basic premise for use of glucose oxidase (that glucose content in tracheal secretions is solely related to aspiration of glucose-containing formulation) has been shown to be invalid, and its use is thwarted by poor sensitivity/ specificity characteristics (177) .
D6. Development of diarrhea associated with enteral tube feedings warrants further evaluation for etiology (grade E).
Rationale. Diarrhea in the ICU patient receiving EN should prompt an investigation for excessive intake of hyperosmolar medications, such as sorbitol, use of broad-spectrum antibiotics, Clostridium difficile pseudomembranous colitis, or other infectious etiologies. Most episodes of nosocomial diarrhea are mild and selflimiting (178) .
Assessment should include an abdominal exam, fecal leukocytes, quantification of stool, stool culture for C. difficile (and/or toxin assay), serum electrolyte panel (to evaluate for excessive electrolyte losses or dehydration), and review of medications. An attempt should be made to distinguish infectious diarrhea from osmotic diarrhea (179 Rationale. In selecting the appropriate enteral formulation for the critically ill patient, the clinician must first decide if the patient is a candidate for a specialty immune-modulating formulation (180) . Patients most likely to show a favorable outcome benefit and thus would be an appropriate candidate for use of immunemodulating formulations include those undergoing major elective GI surgery, trauma (abdominal trauma index scores Ͼ20), burns (total body surface area Ͼ30%), head and neck cancer, and critically ill patients on mechanical ventilation (who are not severely septic) (180). A large body of data suggests that adding pharmaconutrients to enteral formulations provides even further benefits on patient outcome to use of standard formulations alone (181) (182) (183) (Table 12 ) (184 -204) . Studies from basic science have provided a rationale for the mechanism of the beneficial effects seen clinically. Such findings include the discovery of specialized immune (myeloid suppressor) cells, whose role is to regulate the availability of arginine, necessary for normal T-lymphocyte function. These myeloid suppressor cells are capable of causing states of severe arginine deficiency, which impact production of nitric oxide and negatively affect microcirculation. Immune-modulating diets containing arginine and omega-3 fatty acids appear to overcome the regulatory effect of myeloid suppressor cells (205) . Agents such as RNA nucleotides increase total lymphocyte count, lymphocyte proliferation, and thymus function. In a dynamic fashion, the omega-3 fatty acids eicosapentaenoic acid and docosohexaenoic acid displace omega-6 fatty acids from the cell membranes of immune cells. This effect reduces systemic inflammation through the production of alternative biologically less active prostaglandins and leukotrienes. Eicosapentaenoic acid and docosahexaenoic acid (fish oils) have also been shown to down-regulate expression of nuclear factor-kappa B, intracellular adhesion molecule 1, and E-selectin, which in effect decreases neutrophil attachment and transepithelial migration to modulate systemic and local inflammation. In addition eicosapentaenoic acid and docosahexaenoic acid help to stabilize the myocardium and lower the incidence of cardiac arrhythmias, decrease incidence of acute respiratory distress syndrome, and reduce the likelihood of sepsis (206 -209) . Glutamine, considered a conditionally essential amino acid, exerts a myriad of beneficial effects on antioxidant defenses, immune function, production of heat shock proteins, and nitrogen retention. Addition of agents such as selenium, ascorbic acid (vitamin C), and vitamin E provides further antioxidant protection.
Multiple meta-analyses (181, 182, 210 -212) have shown that use of immunemodulating formulations is associated with significant reductions in duration of mechanical ventilation, infectious morbidity, and hospital LOS compared with use of standard enteral formulations. These same five meta-analyses showed no overall impact on mortality from use of immunemodulating formulations (Table 13) (181, 182, 210 -212) . The beneficial outcome effects of the immune-modulating formulations are more uniformly seen in patients undergoing major surgery than in critically ill patients on mechanical ventilation. This influence is even more pronounced when the formulation is given in the preoperative period. By differentiating studies done in surgical ICUs from those done in medical ICUs, Heyland et al showed that the greatest beneficial effect was seen in surgery patients with significant reductions in infectious morbidity (RR ϭ 0.53; 95% CI 0.42-0.68; p Յ 0.05) and hospital LOS (WMD ϭ Ϫ0.76; 95% CI Ϫ1.14 to Ϫ0.37; p Ͻ 0.05) (210) . In contrast, aggregating the data from studies in medical ICU patients showed no effect on infections (RR ϭ 0.96; 95% CI 0.77-1.20; p ϭ not significant), but a similar reduction in hospital LOS (WMD ϭ Ϫ0.47; 95% CI Ϫ0.93 to Ϫ0.01; p ϭ 0.047) (210) .
It has been hypothesized that there may be some increased risk with the use of arginine-containing formulations in medical ICU patients who are severely septic (213, 214) . Based on one level I report (188) , a prospective randomized unblinded study using a control group receiving PN (200) , and a third study published in abstract form only (199) , use of arginine-containing formulations resulted in greater mortality than standard EN and PN formulations. Two of the three studies reporting a potential adverse effect had comparatively lower levels of arginine supplementation (199, 200) . The mechanism proposed for this adverse effect was that in severe sepsis, arginine may be converted to nitric oxide contributing to hemodynamic instability. This concept is contradicted by four other reports. One of these studies showed that infusion of arginine directly into the venous circulation of septic medical and surgical ICU patients caused no hemodynamic stability (215) . Three other studies showed that clinical outcome was better (195, 197) and mortality was reduced in moderately septic ICU patients (196) with use of an arginine-containing formulation (compared with a standard enteral formulation). On review of this controversy, the Guidelines Committee felt that arginine-containing immune-modulating formulations were safe enough to use in mild to moderate sepsis, but that caution should be used if utilized in patients with severe sepsis.
Unfortunately, few studies have addressed the individual pharmaconutrients, their specific effect, or their proper dosing. This body of literature has been criticized for the heterogeneity of studies, performed in a wide range of ICU patient populations, with a variety of experimental and commercial formulations. Multiple enteral formulations are marketed as being immune modulating, but they vary considerably in their makeup and dosage of individual components. It is not clear whether the data from published studies and these subsequent recommendations can be extrapolated to use of formulations that have not been formally evaluated. Based on the strength and uniformity of the data in surgery patients, the Guidelines Committee felt that a grade A recommendation was warranted for use of these formulations in the surgical ICU. The reduced signal strength and heterogeneity of the data in nonoperative critically ill patients in a medical ICU was felt to warrant a B grade recommendation.
For any patient who does not meet the mentioned criteria, there is a much lower likelihood that use of immune-modulating formulations will change outcome. In this situation, the added cost of these specialty formulations cannot be justified and, therefore, standard enteral formulations should be used (180) . 
E2. Patients with acute respiratory distress syndrome and severe acute lung injury should be placed on an enteral
formulation characterized by an antiinflammatory lipid profile (i.e., omega-3 fish oils, borage oil) and antioxidants (grade A).
Rationale. In three level I studies involving patients with acute respiratory distress syndrome, acute lung injury, and sepsis, use of an enteral formulation fortified with omega-3 fatty acids (in the form of eicosapentaenoic acid), borage oil (␥-linolenic acid), and antioxidants was shown to significantly reduce LOS in the ICU, duration of mechanical ventilation, organ failure, and mortality compared with use of a standard enteral formulation (207) (208) (209) . Controversy remains as to the optimal dosage, makeup of fatty acids, and ratio of individual immunemodulating nutrients, which comprise these formulations (Table 14) (207) (208) (209) .
E3. To receive optimal therapeutic benefit from the immune-modulating formulations, at least 50% to 65% of goal energy requirements should be delivered (grade C).
Rationale. The benefit of EN in general (5, 23, 136), and specifically the added value of immune-modulating agents (182, 188, 195) , appears to be a dose-dependent effect. Significant differences in outcome are more likely to be seen between groups randomized to either an immune-modulating or a standard enteral formulation in those patients who receive a "sufficient" volume of feeding (188, 195) . These differences may not be as apparent when all patients who receive any volume of feeding are included in the analysis (195) . E4. If there is evidence of diarrhea, soluble fiber-containing or small peptide formulations may be used (grade E).
Rationale. Those patients with persistent diarrhea (in whom hyperosmolar agents and C. difficile have been excluded) may benefit from use of a soluble fiber-containing formulation or small peptide semielemental formula. The laboratory data, theoretical concepts, and expert opinion would support the use of the peptide-containing enteral formulas but current large prospective trials are not available to make this a strong recommendation (216). Rationale. Probiotics are defined as microorganisms of human origin, which are safe, stable in the presence of gastric acid and bile salts, and confer a health benefit to the host when administered in adequate amounts. Multiple factors in the ICU induce rapid and persistent changes in the commensal microbiota, including broad-spectrum antibiotics, prophylaxis for stress gastropathy, vasoactive pressor agents, alterations in motility, and decreases in luminal nutrient delivery (217, 218) . These agents act by competitive inhibition of pathogenic bacterial growth, blocking epithelial attachment of invasive pathogens, elimination of pathogenic toxins, enhancement of mucosal barrier, and favorably modulating the host inflammatory response (219 -221) . Unfortunately, for the general ICU patient population, there has not been a consistent outcome benefit demonstrated. The most consistent beneficial effect from use of probiotics has been a reduction in infectious morbidity demonstrated in critically ill patients involving transplantation (222, 223) , major abdominal surgery (224) , and trauma (225, 226) . Although some of these studies would warrant a grade B recommendation, the Guidelines Committee felt that the heterogeneity of the ICU populations studied, the difference in bacterial strains, and the variability in dosing necessitated a downgrade to a grade C recommendation. As the ease and reliability of taxonomic classification improve, stronger recommendations for use in specific populations of critically ill patients would be expected (222, 224) . Probiotics in severe acute pancreatitis are currently under scrutiny because of the results of two level II single-center studies showing clinical benefit (significantly reduced infectious morbidity and hospital LOS) (227, 228), followed by a larger level I multicenter study showing increased mortality in those patients receiving probiotics (229) .
F. Adjunctive Therapy
F1. Administration of probiotic agents has been shown to improve outcome (most consistently by decreasing infection) in specific critically ill patient populations involving transplantation
F2. A combination of antioxidant vitamins and trace minerals (specifically including selenium) should be provided to all critically ill patients receiving specialized nutrition therapy (grade B).
Rationale. Antioxidant vitamins (including vitamins E and ascorbic acid) and trace minerals (including selenium, zinc, and copper) may improve patient outcome, especially in burns, trauma, and critical illness requiring mechanical ventilation (230, 231) . A meta-analysis aggregating data from studies evaluating various combinations of antioxidant vitamins and trace elements showed a significant reduction in mortality with their use (RR ϭ 0.65; 95% CI 0.44 -0.97; p ϭ 0.03) (232) . Parenteral selenium, the single antioxidant most likely to improve outcome (233, 234) , has shown a trend toward reducing mortality in patients with sepsis or septic shock (RR ϭ 0.59; 95% CI 0.32-1.08; p ϭ 0.08) (232) . Additional studies to delineate compatibility, optimal dosage, route, and optimal combination of antioxidants are needed. Renal function should be considered when supplementing vitamins and trace elements.
F3. The addition of enteral glutamine to an EN regimen (not already containing supplemental glutamine) should be considered in burn, trauma, and mixed ICU patients (grade B).
Rationale. The addition of enteral glutamine (Table 15) (235) (236) (237) (238) (239) (240) (241) to an EN regimen (nonglutamine supplemented) has been shown to reduce hospital and ICU LOS in burn and mixed ICU patients (235, 237) , and mortality in burn patients alone (237) compared with the same EN regimen without glutamine.
The glutamine powder, mixed with water to a consistency, which allows infusion through the feeding tube, should be given in two or three divided doses to provide 0.3-0.5 g⅐kg Ϫ1 ⅐day Ϫ1 . Although glutamine given by the enteral route may not generate a sufficient systemic antioxidant effect, its favorable impact on outcome may be explained by its trophic influence on intestinal epithelium and maintenance of gut integrity. Enteral glutamine should not be added to an immune-modulating formulation already containing supplemental glutamine (237, 238, 240 Rationale. Three small level II studies using soluble partially hydrolyzed guar gum demonstrated a significant decrease in the incidence of diarrhea in patients receiving EN (242) (243) (244) . However, no differences in days of mechanical ventilation, ICU, LOS, or multiorgan dysfunction syndrome have been reported (242) (243) (244) . Insoluble fiber has not been shown to decrease the incidence of diarrhea in the ICU patient. Cases of bowel obstruction in surgical and trauma patients provided enteral formulations containing insoluble fiber have been reported (245, 246) .
G. When Indicated, Maximize Efficacy of PN
G1. If EN is not available or feasible, the need for PN therapy should be evaluated (see guidelines recommendations B1, B2, B3, C3) (grade C). If the patient is deemed to be a candidate for PN, steps to maximize efficacy (regarding dose, content, monitoring, and choice of supplemental additives) should be used (grade C).
Rationale. As per the discussion for recommendations B1-B3 and C3, a critically ill ICU patient may be an appropriate candidate for PN under certain circumstances:
1. The patient is well nourished before admission, but after 7 days of hospitalization EN has not been feasible or target goal calories have not been met consistently by EN alone. 2. On admission, the patient is malnourished and EN is not feasible. 3. A major surgical procedure is planned, the preoperative assessment indicates that EN is not feasible through the perioperative period, and the patient is malnourished.
For these patients, a number of steps may be used to maximize the benefit or efficacy of PN while reducing its inherent risk from hyperglycemia, immune suppression, increased oxidative stress, and potential infectious morbidity (24, 92). The grade of the first recommendation is based on the strength of the literature for recommendations B1-B3 and C3, while that of the second is based on the supportive data for recommendations G2-G6. 
G2. In all ICU patients receiving PN, mild permissive underfeeding should be considered, at least initially. Once energy requirements are determined, 80% of these requirements should serve as the ultimate goal or dose of parenteral feeding (grade C). Eventually, as the patient stabilizes, PN may be increased to meet
energy requirements (grade E). For obese patients (BMI Ն30), the dose of PN with regard to protein and caloric provision should follow the same recommendations given for EN in guideline recommendation C5 (grade D).
Rationale. "Permissive underfeeding" in which the total caloric provision is determined by 80% of energy requirements (calculated from simplistic equations such as 25 kcal/kg actual body weight/day, published predictive equations, or as measured by indirect calorimetry) will optimize efficacy of PN. This strategy avoids the potential for insulin resistance, greater infectious morbidity, or prolonged duration of mechanical ventilation and increased hospital LOS associated with excessive energy intake. Lower dose hypocaloric PN in two studies was shown to reduce the incidence of hyperglycemia (247) and infections, ICU and hospital LOS, and duration of mechanical ventilation compared with higher eucaloric doses of PN (248) (Table  16 ) (247) (248) (249) (250) .
G3. In the first week of hospitalization in the ICU, when PN is required and EN is not feasible, patients should be given a parenteral formulation without soybased lipids (grade D).
Rationale. This recommendation is controversial, and is supported by a single level II study (which was also included in the hypocaloric vs. eucaloric dosing in recommendation G2 above) (248) . The recommendation is supported by animal data (251), with further support from EN studies (252) , where long-chain fatty acids have been shown to be immunosuppressive. In North America at the present time, the choice of parenteral lipid emulsion is severely limited to a soy-based 18-carbon omega-6 fatty acid preparation (which has proinflammatory characteristics in the ICU population). During the first 7 days, soy-based lipid-free PN has been shown to be associated with a significant reduction in infectious morbidity (pneumonia and catheter-related sepsis), decreased hospital and ICU LOS, and shorter duration of mechanical ventilation compared with use of lipid-containing PN (248) . Combining the data from two studies (248, 250) , a meta-analysis by Heyland et al confirmed a significant reduction in infectious morbidity (RR ϭ 0.63; 95% CI 0.42-0.93; p ϭ 0.02) in the groups receiving no soy-based lipids (21). Application of this recommendation should be done with caution. These two studies were done before the Van den Berghe et al (253, 254) studies, and full dose PN without lipids might exacerbate stress-induced hyperglycemia. Although two favorable level II studies would generate a grade C recommendation, the implications from a practical standpoint led to a downgrade of the recommendation to grade D (Table 17) (248, 250) .
G4. A protocol should be in place to promote moderately strict control of serum glucose when providing nutrition supthat port therapy (grade B). A range of 110 -150 mg/dL may be most appropriate (grade E).
Rationale. Strict glucose control, keeping serum glucose levels between 80 and 110 mg/dL, has been shown in a large single-center trial to be associated with reduced sepsis, reduced ICU LOS, and lower hospital mortality, when compared with conventional insulin therapy (keeping blood glucose levels Ͻ200 mg/dL) (253) . The effect was more pronounced in surgical ICU than medical ICU patients (254) (Table 18 ) (253) (254) (255) .
A large level I multicenter European study suggested that moderate control (keeping glucose levels between 140 and 180 mg/dL) might avoid problems of hypoglycemia and subsequently reduce the mortality associated with hypoglycemia compared with tighter control (255) . With a paucity of data, the Guidelines Committee felt attempting to control glucose in the range of 110 -150 mg/dL was most appropriate at this time. G5. When PN is used in the critical care setting, consideration should be given to supplementation with parenteral glutamine (grade C).
Rationale. The addition of parenteral glutamine (at a dose of 0.5 g⅐kg Ϫ1 ⅐day Ϫ1 ) to a PN regimen has been shown to reduce infectious complications (121, 256) , ICU LOS (257), and mortality (258) in critically ill patients, compared with the same PN regimen without glutamine. A meta-analysis by Heyland et al combining results from nine studies, confirmed a trend toward reduced infection (RR ϭ 0.75; 96% CI 0.54 -1.04; p ϭ 0.08) and a significant reduction in mortality (RR ϭ 0.67; 95% CI 0.48 -0.92; p ϭ 0.01) in groups receiving PN with parenteral glutamine vs. those groups getting PN alone (21) (Table 19) (121, 256 -264) .
The proposed mechanism of this benefit relates to generation of a systemic antioxidant effect, maintenance of gut integrity, induction of heat shock proteins, and use as a fuel source for rapidly replicating cells. Of note, the dipeptide form of parenteral glutamine (Dipeptiven and Glamin; Fresenius Kabi, Uppsala, Sweden) upon which most of these data are based is widely used in Europe but not commercially available in North America (referring both to United States and Canada). Use of L-glutamine, the only source of parenteral glutamine available in North America, is severely limited by problems with stability and solubility (100 mL water per 2 g glutamine) (256, 264 -267) . All three reports that showed a positive clinical effect were level II studies (121, 256, 258) Rationale. Because of the marked benefits of EN for the critically ill patient, repeated efforts to initiate enteral therapy should be made. To avoid the complications associated with overfeeding, the amount of calories delivered by the parenteral route should be reduced appropriately to compensate for the increase in the number of calories being delivered enterally. Once the provision of enteral feeding exceeds 60% of target energy requirements, PN may be terminated. Rationale. There is a lack of consensus about the optimum source and composition of lipid (medium-vs. long-chain triglyceride, soybean oil, olive oil, omega-3 fatty acids, 10% or 20% solution) in enteral and parenteral formulations for the patient with respiratory failure. One small level II study (20 patients) showed a clinical benefit (reduced duration of mechanical ventilation) from use of a highfat, low-carbohydrate enteral formulation, compared with a standard formulation (268) . A second smaller level II study (10 patients) showed no clinical benefit (269) .
H. Pulmonary Failure
Results from uncontrolled studies would suggest that increasing the composite ratio of fat to carbohydrate becomes clinically significant in lowering CO 2 production only in the ICU patient being overfed, that composition is much less likely to affect CO 2 production when the design of the nutrition support regimen approximates caloric requirements (270) . Effort should be made to avoid total caloric provision that exceeds energy requirements, as CO 2 production increases significantly with lipogenesis and may be tolerated poorly in the patient prone to CO 2 retention (268 -270) . Rapid infusion of fat emulsions (especially soybean-based), regardless of the total amount, should be avoided in patients suffering from severe pulmonary failure.
H2. Fluid-restricted calorically dense formulations should be considered for patients with acute respiratory failure (grade E).
Rationale. Fluid accumulation and pulmonary edema are common in patients with acute respiratory failure and have been associated with poor clinical outcomes. It is, therefore, suggested that a fluid-restricted calorically dense nutrient formulation (1.5-2.0 kcal/mL) be considered for patients with acute respiratory failure that necessitates volume restriction (269) .
H3. Serum phosphate levels should be monitored closely, and replaced appropriately when needed (grade E).
Rationale. Phosphate is essential for the synthesis of adenosine triphosphate and 2,3-diphosphoglycerate, both of which are critical for normal diaphragmatic contractility and optimal pulmonary function. LOS and duration of mechanical ventilation are increased in patients who become hypophosphatemic when compared with those who do not have this electrolyte imbalance. As suggested by several uncontrolled studies, it seems prudent to monitor phosphate closely and replace appropriately when needed (271, 272 Rationale. Acute renal failure seldom exists as an isolated organ failure in critically ill patients. When prescribing EN to the ICU patient, the underlying disease process, preexisting comorbidities, and current complications should be taken into account. Specialty formulations lower in certain electrolytes (i.e., phosphate and potassium) than standard products may be beneficial in the ICU patient with acute renal failure (273) (274) (275) Rationale. There is an approximate amino acid loss of 10 -15 g/day during continuous renal replacement therapy. Providing less than 1 g protein⅐kg
Ϫ1
⅐day
Ϫ1 of protein may result in increased nitrogen At least one randomized prospective trial (276) has suggested an intake of 2.5 g⅐kg Ϫ1 ⅐day Ϫ1 is necessary to achieve positive nitrogen balance in this patient population (276 -278) . Rationale. Although malnutrition is highly prevalent among patients with chronic liver disease and nearly universal among patients awaiting liver transplantation, the clinical consequences of liver failure render traditional nutritional assessment tools to be inaccurate and unreliable. The primary etiology of malnutrition is poor oral intake, stemming from multiple factors. Malnutrition in patients with cirrhosis leads to increased morbidity and mortality rates. Furthermore, patients who are severely malnourished before transplant surgery have a higher rate of complications and a decreased overall survival rate after liver transplantation. Energy needs in critically ill patients with liver disease are highly variable, difficult to predict by simple equations in liver disease and consequently are best determined by indirect calorimetry in ICU patients with liver disease (279 -287) .
J. Hepatic Failure
J1. Traditional assessment tools should be used with caution in patients with cirrhosis and hepatic failure, as these
J2. EN is the preferred route of nutrition therapy in ICU patients with acute and/or chronic liver disease. Nutrition regimens should avoid restricting protein in patients with liver failure (grade E).
Rationale. Nutrition therapy is essential in patients with end-stage liver disease and during all phases of liver transplantation. Enteral feeding has been associated with decreased infection rates and fewer metabolic complications in liver disease and after liver transplant when compared with PN. Long-term PN can be associated with hepatic complications, including worsening of existing cirrhosis and liver failure with the concomitant risks of sepsis, coagulopathy, and death. Nutrition-associated cholestasis usually present with prolonged PN is also a significant problem. EN improves nutrition status, reduces complications and prolongs survival in liver disease patients and is, therefore, recommended as the optimal route of nutrient delivery. Protein should not be restricted as a management strategy to reduce risk of developing hepatic encephalopathy (279, 282) . Protein requirements for the patient with hepatic failure should be determined in the same manner as for the general ICU patient (per recommendations C4 and C5).
J3. Standard enteral formulations should be used in ICU patients with acute and chronic liver disease. The branched-chain amino acid formulations should be reserved for the rare encephalopathic patient who is refractory to STD with luminal acting antibiotics and lactulose (grade C).
Rationale. There is no evidence to suggest that a formulation enriched in branched-chain amino acid improves patient outcomes compared to standard whole protein formulations in critically ill patients with liver disease. Findings from level II randomized outpatient trials suggest that long-term (12 and 24 months) nutritional supplementation with oral branched-chain amino acid granules may be useful in slowing the progression of hepatic disease and/or failure and prolonging event-free survival. In patients with hepatic encephalopathy refractory to STD, use of branched-chain amino acid formulations may improve coma grade compared with standard formulations (279, 288 -292) .
K. Acute Pancreatitis
K1. On admission, patients with acute pancreatitis should be evaluated for disease severity (grade E). Patients with severe acute pancreatitis should have a nasoenteric tube placed and EN initiated as soon as fluid volume resuscitation is complete (grade C).
Rationale. Based on the Atlanta Classification, patients with severe acute pancreatitis may be identified on admission by the presence of organ failure and/or the presence of local complications within the pancreas on computerized tomography scan, complemented by the presence of unfavorable prognostic signs (293, 294) . Organ failure is defined by shock (systolic blood pressure Ͻ90 mm Hg), pulmonary insufficiency (PaO 2 Ͻ60 mm Hg), renal failure (serum creatinine Ͼ2 mg/dL), or GI bleeding (Ͼ500 mL blood loss within 24 hours). Local complications on computerized tomography scan include pseudocyst, abscess, or necrosis. Unfavorable prognostic signs are defined by an Acute Physiology and Chronic Health Evaluation II score of Ն8, or by Ն3 Ranson Criteria (293, 294) . Patients with severe acute pancreatitis have an increased rate of complications (38%) and a higher mortality (19%) than patients with mild to moderate disease, and have close to 0% chance of advancing to oral diet within 7 days (97, 295, 296) . Loss of gut integrity with increased intestinal permeability is worse with greater disease severity (9).
Patients with severe acute pancreatitis will experience improved outcome when provided early EN. Rationale. Patients with mild to moderate acute pancreatitis have a much lower rate of complications (6%) than patients with more severe disease, have close to a 0% mortality rate, and have an 81% chance of advancing to oral diet within 7 days (97, 295, 296) . Providing nutrition support therapy to these patients does not appear to change outcome. Of three level II randomized studies that included patients with less disease severity (62% to 81% of patients had mild to moderate acute pancreatitis), none showed significant outcome benefits with use of EN compared with PN (8, 46, 55). Provision of nutrition support therapy in these patients should be considered if a subsequent unanticipated complication develops (e.g., sepsis, shock, organ failure) or the patient fails to advance to oral diet after 7 days of hospitalization.
K3. Patients with severe acute pancreatitis may be fed enterally by the gastric or jejunal route (grade C).
Rationale. Two level II prospective randomized trials comparing gastric with jejunal feeding in severe acute pancreatitis showed no significant differences between the two levels of EN infusion within the GI tract (299, 300) . The success of gastric feeding in these two studies (where only two patients in the Eatock group [299] and one patient in the Kumar group [300] experienced increased pain only without a need to reduce the infusion rate) was attributed to early initiation of feeding within 36 -48 hours of admission, thereby minimizing the degree of ileus (299) .
K4. Tolerance to EN in patients with severe acute pancreatitis may be enhanced by the following measures:
• Minimizing the period of ileus after admission by early initiation of EN (grade D).
• Displacing the level of infusion of EN more distally in the GI tract (grade C).
• Changing the content of the EN delivered from intact protein to small peptides, and long-chain fatty acids to medium-chain triglycerides or a nearly fatfree elemental formulation (grade E).
• Switching from bolus to continuous infusion (grade C).
Rationale.
In a prospective level III study, Cravo et al showed that the longer the period of ileus and the greater the delay in initiating EN, the worse the tolerance (and the greater the need to switch to PN) in patients admitted with severe acute pancreatitis. Delays of Ն6 days resulted in 0% tolerance of EN, whereas initiating EN within 48 hours was associated with 92% tolerance (301) .
Feeding higher in the GI tract is more likely to stimulate pancreatic exocrine secretion, which may invoke greater difficulties with tolerance. Conversely, feeding into the jejunum 40 cm or more below the ligament of Treitz is associated with little or no pancreatic exocrine stimulation (302) . In a level II prospective trial, McClave et al (46) showed varying degrees of tolerance with different levels of infusion within the GI tract. Three patients who tolerated deep jejunal feeding with an EN formulation developed an uncomplicated exacerbation of symptoms with advancement to oral clear liquids (an effect reversed by return to jejunal feeding). One patient who showed tolerance to jejunal feeds had an exacerbation of the systemic inflammatory response syndrome when the tube was displaced back into the stomach (an effect again reversed by return to jejunal feeding) (46).
At the same level of infusion within the GI tract, content of EN formulation may be a factor in tolerance. In a prospective case series, patients hospitalized for acute pancreatitis who could not tolerate a regular diet, showed resolution of symptoms and normalization of amylase levels after switching to an oral, nearly fat-free elemental EN formulation (303) . In a patient operated on for complications of severe acute pancreatitis, feeding a nearly fat-free elemental EN formulation had significantly less pancreatic exocrine stimulation (measured by lipase output from the ampulla) than a standard EN formulation with intact long-chain fatty acids infused at the same level of the jejunum (304) .
The manner of infusion of EN also affects tolerance. A small level II randomized trial showed that continuous infusion of EN into the jejunum (100 mL over 60 minutes) was associated with significantly less volume, bicarbonate, and enzyme output from the pancreas than the same volume given as an immediate bolus (305). It is not clear whether the data from this study can be extrapolated to gastric feeding. (Note: The Guidelines Committee does not recommend bolus feeding into the jejunum.)
K5. For the patient with severe acute pancreatitis, when EN is not feasible, use of PN should be considered (grade C). PN should not be initiated until after the first 5 days of hospitalization (grade E).
Rationale. For patients with severe acute pancreatitis when EN is not feasible, timing of initiation of PN (and the choice between PN and STD) becomes an important issue. In an early level II randomized trial, Sax et al (97) showed net harm from use of PN initiated within 24 hours of admission for patients with mild to moderate acute pancreatitis, with significantly longer hospital LOS than those patients randomized to STD (no nutrition support therapy). In contrast, a later level II study by Xian-Li et al (121) in patients with severe pancreatitis where PN was initiated 24 -48 hours after "full liquid resuscitation," significant reductions in overall complications, hospital LOS, and mortality were seen when compared with STD. The design of this latter study may have led to a differential delay of several days in the initiation of PN, possibly after the peak of the inflammatory response (17). The grade of the first recommendation (to consider use of PN) is based on the results of the level II study by Xian-Li et al (121) , whereas the grade for the second recommendation (regarding the timing of PN) is based on expert opinion and interpretation of the discrepancy between these two reports (97, 121 
